ArticlePLoS neglected tropical diseases2019
Feasibility of a point-of-care test based on quantum dots with a mobile phone reader for detection of antibody responses.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Accuracy of immunological tests on serum and urine for diagnosis of Taenia solium neurocysticercosis: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis.Open forum infectious diseases · 2026Article
- Serological diagnosis of cysticercosis in humans and pigs: status, limitations, and prospects.Frontiers in veterinary science · 2025Review
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Insights into the diagnosis, vaccines, and control of Taenia solium, a zoonotic, neglected parasite.Parasites & vectors · 2023Review
- Deep learning on lateral flow immunoassay for the analysis of detection data.Frontiers in computational neuroscience · 2023Article
- Lateral flow immunoassay strips based on europium(III) chelate microparticle for the rapid and sensitive detection ofFrontiers in cellular and infection microbiology · 2022Article
- Article
- Neurocysticercosis: Current Perspectives on Diagnosis and Management.Frontiers in veterinary science · 2021Review
- Development of point-of-care tests forPathogens and global health · 2019Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
We developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. We evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen. It was a retrospective study by examining 112 positive human sera from patients with neurocysticercosis (NCC) including samples from patients with single viable cyst (n = 18), two or more viable cysts (n = 71), and subarachnoid (racemose) cysts (n = 23). These samples were collected from previous study subjects in Lima, Peru under an approved study protocol in Peru. The sera were made anonymous under a protocol approved by the CDC Institutional Review Board. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging. To test the specificity of the assay, we evaluated a panel of serum samples obtained from patients with other infections (n = 24), and serum samples from persons in the United States and Egypt who had not traveled outside their country, and therefore are presumed negative for cysticercosis (n = 128). The assay specificity in the negative panel was 99% (95-100%) while assay sensitivity was 89% (79-95%) in NCC patients with two or more viable cysts. Our assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.